Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 981-991

  Chen, Yu ^a   Clegg, Nicola J ^a   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DEXAMETHASONE; DOCETAXEL; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; MDV 3100; MIFEPRISTONE; NILUTAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; CASTRATION; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DIARRHEA; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; NONHUMAN; ORCHIECTOMY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; TESTOSTERONE BLOOD LEVEL; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 70349395222     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70229-3     Document Type: Review

References (76)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Scher H.I., and Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 (2000) 323-327
3. Scher H.I., Steineck G., and Kelly W.K. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46 (1995) 142-148
4. Griffin J.E. Androgen resistance-the clinical and molecular spectrum. N Engl J Med 326 (1992) 611-618
5. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
6. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
7. Edwards J., Krishna N.S., Grigor K.M., and Bartlett J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89 (2003) 552-556
8. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
9. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
10. Taplin M.E., Rajeshkumar B., Halabi S., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21 (2003) 2673-2678
11. Hara T., Miyazaki J., Araki H., et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63 (2003) 149-153
12. Yoshida T., Kinoshita H., Segawa T., et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65 (2005) 9611-9616
13. Steinkamp M.P., O'Mahony O.A., Brogley M., et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69 (2009) 4434-4442
14. Mellinghoff I.K., Vivanco I., Kwon A., Tran C., Wongvipat J., and Sawyers C.L. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 (2004) 517-527
15. Mahajan N.P., Liu Y., Majumder S., et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 104 (2007) 8438-8443
16. Guo Z., Dai B., Jiang T., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 (2006) 309-319
17. Mulholland D.J., Dedhar S., Wu H., and Nelson C.C. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25 (2006) 329-337
18. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315-4319
19. Comuzzi B., Lambrinidis L., Rogatsch H., et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162 (2003) 233-241
20. Wang Y., Kreisberg J.I., Bedolla R.G., Mikhailova M., deVere White R.W., and Ghosh P.M. A 90 kDa fragment of filamin A promotes casodex-induced growth inhibition in casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene 26 (2007) 6061-6070
21. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
22. Montgomery R.B., Mostaghel E.A., Vessella R., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68 (2008) 4447-4454
23. Chen Y., Sawyers C.L., and Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8 (2008) 440-448
24. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
25. Taplin M.E., Manola J., Oh W.K., et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 101 (2008) 1084-1089
26. Labrie C., Cusan L., Plante M., Lapointe S., and Labrie F. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J Steroid Biochem 28 (1987) 379-384
27. Labrie F., Dupont A., and Bellanger A. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgen. Prostate 4 (1983) 579-584
28. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
29. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
30. Dijkman G.A., Janknegt R.A., De Reijke T.M., and Debruyne F.M. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 158 (1997) 160-163
31. Schellhammer P.F., Sharifi R., Block N.L., et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 50 (1997) 330-336
32. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 164 (2000) 1579-1582
33. Bales G.T., and Chodak G.W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47 1A suppl (1996) 38-43
34. Tyrrell C.J., Kaisary A.V., Iversen P., et al. A randomised comparison of 'casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 (1998) 447-456
35. Kelly W.K., and Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149 (1993) 607-609
36. Schellhammer P.F., Venner P., Haas G.P., et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157 (1997) 1731-1735
37. Matias P.M., Donner P., Coelho R., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275 (2000) 26164-26171
38. Sack J.S., Kish K.F., Wang C., et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98 (2001) 4904-4909
39. He B., Gampe Jr. R.T., Kole A.J., et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16 (2004) 425-438
40. Shang Y., Myers M., and Brown M. Formation of the androgen receptor transcription complex. Mol Cell 9 (2002) 601-610
41. Shiau A.K., Barstad D., Loria P.M., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
42. Bohl C.E., Gao W., Miller D.D., Bell C.E., and Dalton J.T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102 (2005) 6201-6206
43. Masiello D., Cheng S., Bubley G.J., Lu M.L., and Balk S.P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277 (2002) 26321-26326
44. Hodgson M.C., Astapova I., Hollenberg A.N., and Balk S.P. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 67 (2007) 8388-8395
45. Bergerat J.P., and Ceraline J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30 (2009) 145-157
46. Feng S., Tang Q., Sun M., Chun J.Y., Evans C.P., and Gao A.C. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8 (2009) 665-671
47. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009) 787-790
48. Wakabayashi K., Imai K., Miyachi H., Hashimoto Y., and Tanatani A. 4-(Anilino)pyrrole-2-carboxamides: novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor. Bioorg Med Chem 16 (2008) 6799-6812
49. McGinley P.L., and Koh J.T. Circumventing anti-androgen resistance by molecular design. J Am Chem Soc 129 (2007) 3822-3823
50. Attar R.M., Jure-Kunkel M., Balog A., et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signalling for the treatment of prostate cancer. Cancer Res 69 (2009) 6522-6530
51. Cantin L., Faucher F., Couture J.F., et al. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 282 (2007) 30910-30919
52. Singh P., Hallur G., Anchoori R.K., et al. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate 68 (2008) 1570-1581
53. Jones J.O., An W.F., and Diamond M.I. AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol 4 (2009) 191-197
54. Scher H.I., Beer T.M., Higano C.S., et al. Antitimor activity of MDV3100 in a phase 1/2 study of castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol 27 15 suppl (2009) 5011
55. De Bono J.S., Attard G., Reid A.H., et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol 26 15 suppl (2008) 5005
56. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14 (2008) 6302-6309
57. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., and Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68 (2008) 5469-5477
58. Hu R., Dunn T.A., Wei S., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (2009) 16-22
59. Flitsch J., Bernreuther C., Hagel C., and Ludecke D.K. Hypophysectomy for prostate cancer: a revival of old knowledge?. J Neurosurg 109 (2008) 760-764
60. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L., and Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7 (1989) 590-597
61. Fossa S.D., Slee P.H., Brausi M., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19 (2001) 62-71
62. Plowman P.N., Perry L.A., and Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br J Urol 59 (1987) 255-257
63. Ahmann F.R., Crawford E.D., Kreis W., and Levasseur Y. Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone. Cancer Res 47 (1987) 4736-4739
64. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025-1033
65. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., and Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50 (1994) 267-273
66. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325
67. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
68. Danila D.C., Rathkopf D.E., Morris M.J., et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. Proc Am Soc Clin Oncol 26 15 suppl (2008) 5019
69. Ryan C., Smith M.R., Rosenberg J.E., et al. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol 26 15 suppl (2008) 5018
70. Vasaitis T., Belosay A., Schayowitz A., et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7 (2008) 2348-2357
71. Hille U.E., Hu Q., Vock C., et al. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. Eur J Med Chem 44 (2009) 2765-2775
72. Thomas L.N., Douglas R.C., Lazier C.B., Too C.K., Rittmaster R.S., and Tindall D.J. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 53 (2008) 244-252
73. Shao T.C., Li H., Ittmann M., and Cunningham G.R. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol 178 4 Pt 1 (2007) 1521-1527
74. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (2006) 4072-4079
75. Shah S.K., Trump D.L., Sartor O., et al. Phase 2 study of dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 181 (2009) 621-626
76. Taplin M., Ko Y., Regan M.M., et al. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol 26 15 suppl (2008) 5068